Is Aurinia Pharmaceuticals (AUPH) Undervalued On Raised Guidance And Stronger LUPKYNIS Sales?

Aurinia Pharmaceuticals (AUPH) has just put fresh numbers on the table, posting third quarter 2026 earnings and lifting its full year revenue outlook after stronger LUPKYNIS driven performance.

Aurinia Pharmaceuticals has seen moderate momentum build, with a 90 day share price return of 3.85% and a year to date share price gain of 7.23%. The 3 year total shareholder return of 112.66% points to much stronger longer term compounding than the recent 30 day move of 2.81% alone might suggest.

Spot 19 high quality undiscovered gems that show similar earnings momentum and product-driven stories to Aurinia Pharmaceuticals so you can compare this quarter's update with other under-the-radar opportunities.

Aurinia Pharmaceuticals now trades at a sizeable intrinsic value discount and sits roughly 10% below the average analyst target after a solid run. Is that gap a bargain, or a warning sign that the market’s caution is justified?

Most Popular Narrative: 10% Undervalued

Aurinia Pharmaceuticals closed at $16.46 against a widely followed fair value of $18.29, so the current setup hinges on how durable LUPKYNIS and the autoimmune pipeline really are over the next few years.

The build out of a broader autoimmune portfolio, including aritinercept in Phase 2 studies across several indications and the addition of zetomipzomib through the Kezar Life Sciences acquisition, may be viewed as a pipeline that is already partially recognized in Aurinia Pharmaceuticals current market value, limiting further uplift in expected long term revenue and margin expansion until later stage data arrives.

See why 17 investors see Aurinia Pharmaceuticals as 10% undervalued.

Result: Fair Value of $18.29 (UNDERVALUED)

Still, the Aurinia Pharmaceuticals story can shift quickly if LUPKYNIS loses ground in lupus nephritis or if governance concerns start to weigh on the P/E multiple.

Find out about the key risks to this Aurinia Pharmaceuticals narrative.

Next Steps

Mixed signals on Aurinia Pharmaceuticals can either be a reason to wait or a cue to get closer to the data yourself. Take a moment to weigh both the upsides and pressure points by reviewing the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Aurinia Pharmaceuticals?

If Aurinia Pharmaceuticals has your attention, do not stop here. Broader context can help you identify patterns, pressure points, and potential opportunities before others react.

• Target resilient balance sheets and steadier fundamentals by reviewing the list of solid balance sheet and fundamentals (24 results) that already clear tough financial quality filters.
• Prioritize quality at a discount and compare Aurinia Pharmaceuticals with the 39 high quality undervalued stocks that currently trade below their assessed intrinsic value.
• Focus on consistent income streams by lining up Aurinia Pharmaceuticals against the 8 dividend fortresses that pair higher yields with robust underlying businesses.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com